Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.
Vaccitech, a UK-based vaccine developer spun out of University of Oxford, priced its shares at $17 yesterday and will raise more than $110m when it begins trading on the Nasdaq Global Market today.
The spinout will issue 6.5 million American Depositary Shares (ADSs), representing the same number of ordinary shares. It will trade using the ticker symbol VACC.
Founded in 2016, Vaccitech initially aimed to develop a universal flu vaccine but the technology’s arguably most fundamental impact…
